Shareholder rights firm Robbins Umeda LLP announces an investigation into Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP). Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Gregory E. Del Gaizo at (800) 350-6003, inquiry@robbinsumeda.com, or via the shareholder information form on the firm's website.

Robbins Umeda LLP is investigating whether officers or directors at Chelsea Therapeutics issued materially false and misleading statements to investors that were designed to deceive the market and artificially inflate the company's stock price. In particular, the firm is examining allegations that senior officials at Chelsea Therapeutics misled investors by failing to accurately disclose material information about the commercial viability, effectiveness, and market potential for NORTHERA, an experimental drug developed by the company for the treatment of neurogenic disorders like Parkinson's disease.

Presently, the U.S. Food and Drug Administration (the "FDA") is reviewing Chelsea Therapeutics' New Drug Application for NORTHERA. On February 13, 2012, Chelsea Therapeutics issued a press release that revealed that the company received an FDA briefing document that outlined concerns related to the agency's risk-benefit analysis for NORTHERA. According to the company's press release, the FDA highlighted concerns related to "the short duration of our clinical studies [and] the limited size of our study population given the orphan indication and the challenges in quantifying symptomatic and clinical benefit."

Since these facts have emerged, shares of Chelsea Therapeutics have lost over 38% of their value. After recently trading as high as $5.20 per share on February 8, 2012, shares of Chelsea Therapeutics' common stock closed on February 13, 2012, at just $3.11 per share.

Robbins Umeda LLP highlights that one option available to Chelsea Therapeutics' shareholders is filing a class action lawsuit on behalf of investors to recover damages incurred as a result of the wrongdoing.

Robbins Umeda LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.

Press release link: http://www.robbinsumeda.com/shareholders-rights-blog/chelsea-therapeutics/

Attorney Advertising. Past results do not guarantee a similar outcome.

Robbins Umeda LLP
Gregory E. Del Gaizo
(619) 525-3990 or Toll Free (800) 350-6003
inquiry@robbinsumeda.com
www.robbinsumeda.com